Remazolam besylate

Phase 3Small molecule

FFirst Affiliated Hospital of Ningbo University

Remazolam besylate is one of 2 small molecule programs targeting Remimazolam Besylate. It is currently in Phase 3.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Remimazolam BesylateRecruiting

Remimazolam BesylatePhase 3

Recruiting

Competition

Competitive Landscape

3 competitors in Remimazolam Besylate

#DrugCompanyPhaseTrials

Ondexxya

UUnion Hospital, Tongji Medical College, Huazhong University of Science and Technology

Phase 3

3 2

Remazolam besylate

FFirst Affiliated Hospital of Ningbo University

Phase 3

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Sedation1 trial

Effect of Remazolam Besylate Combined With Remifentanil Analgesic Sedation on the Prognosis of Patients With Sepsis

Enrolling by invitation·FFirst Affiliated Hospital of Ningbo University·Phase 4·NCT06731088·100 enrolled

Remimazolam Besylate1 trial

Sedative Effect and Safety of Remimazolam Besylate in ARDS Patients

Recruiting·ZZhiming Jiang·Phase 4·NCT05758597·100 enrolled

Sources

References

[1]
ClinicalTrials.gov — 2 trial records for Remazolam besylate. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Remazolam besylate compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Remazolam besylate. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — First Affiliated Hospital of Ningbo University company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 3[1]
Company: FFirst Affiliated Hospital of Ningbo University

Remazolam besylate

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

Sedation1 trial

Remimazolam Besylate1 trial

References

Drug Info

Quick Facts

Related News